MedTrace Logo

CD49 in Optimization The Cologenicity of Mesenchymal Stem Cell Culture Passage

NCT05093725 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2021-10-26

No results posted yet for this study

Summary

Human mesenchymal stem cells (MSCs) due to their regenerative and immunomodulatory properties are widely used for the treatment of bone and cartilage damage, cardiovascular, gastrointestinal, autoimmune, neurodegenerative diseases and cancer .It is shown that the use of MSCs in therapy is safe and can be effective .In 2006, the International Society for Cellular Therapy (ISCT) proposed the minimal criteria to define human MSCs. First, MSCs must be plastic-adherent when maintained in the standard culture conditions. Second MSCs must express CD105, CD73 and CD90, and lack expression of CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR surface molecules.

Conditions

  • Umbilical Cord of Normal Labor

Interventions

DEVICE

flow cytomery

take sample of Wharton jelly and culturing it to know the best time for mesenchymal stem cell growth

Sponsors & Collaborators

  • Sohag University

    lead OTHER

Eligibility

Min Age
1 Day
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-11-30
Primary Completion
2022-06-30
Completion
2022-06-30

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05093725 on ClinicalTrials.gov